NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT06370013 2024-04-17Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid TumorsTransThera Sciences (Nanjing), Inc.Available